dabigatran has been researched along with Cardiovascular Diseases in 37 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 35 (94.59) | 24.3611 |
| 2020's | 2 (5.41) | 2.80 |
| Authors | Studies |
|---|---|
| Barrios, V; Escobar, C | 1 |
| Bernardini, F; Marchetti, G; Romoli, M; Urbinati, S | 1 |
| Chang, S; Chang, Y; Lu, S; Sun, Q; Zhang, Y | 1 |
| Eek, AK; Granas, AG; Øie, E | 1 |
| Arena, G; Baratta, A; Bianchi, S; Catarzi, S; Conti, A; Covelli, A; Dell'Amico, I; Mazzucchelli, M; Molesti, D; Orlandi, G; Pampana, A; Perrotta, ME; Tognarelli, A; Torri, T | 1 |
| Gottsäter, A | 1 |
| Amin, A; Baker, CL; Carda, E; Dhamane, A; Dina, O; Keshishian, A; Mardekian, J; Nadkarni, A; Rosenblatt, L; Russ, C; Yuce, H | 1 |
| Agewall, S; Andreotti, F; Atar, D; Cattaneo, M; Collet, JP; Grove, EL; Huber, K; Husted, S; Kjeldsen, K; Lip, GY; Morais, J; Pathak, A; Rosano, G; Storey, RF; Verheugt, FW; Wassmann, S | 1 |
| Stiefelhagen, P | 1 |
| Attia, JR; Pearce, R | 1 |
| Bazargan, A; Douglas, G; McKenzie, JL | 1 |
| Hughes, DA; Pink, J; Pirmohamed, M | 1 |
| Cameron, C; Coyle, D; Coyle, K; Kelly, S; Lee, K; Steiner, S; Wells, GA | 1 |
| Bertoletti, L; Da Costa, A; Durupt, S; Epinat, M; Laporte, S; Lega, JC; Mismetti, P | 1 |
| Finsterer, J; Krutisch, G; Stöllberger, C | 1 |
| Barillari, G; Cheng, JW | 1 |
| Douketis, J; Ing, E | 1 |
| Bruyère, O; Buckinx, F; Dogné, JM; Douxfils, J; Hainaut, P; Minet, V; Mullier, F; Rabenda, V; Reginster, JY | 1 |
| Amirehsani, KA; Scott, KA | 1 |
| Aleil, B; Krieger, C; Stephan, D | 1 |
| Lane, DA; Lee, SI; Lip, GY; Sayers, M | 1 |
| Drambarean, B; Hellenbart, E; Lee, J; Nutescu, EA | 1 |
| Eikelboom, J; Weitz, JI | 1 |
| Chan, YH; Chang, SH; Kuo, CT; Lee, HF; See, LC; Tu, HT; Wu, LS; Yeh, YH; Yen, KC | 1 |
| Al-Khalili, F; Benson, L; Lindström, C | 1 |
| Johansson, PI; Ostrowski, SR; Solbeck, S; Stensballe, J | 1 |
| Hussain, SS; Mukherjee, D; Tyroch, AH | 1 |
| Dellegrottaglie, S; Filippatos, G; Giugliano, RP; Lund, LH; Magnani, G; McMurray, J; Perrone-Filardi, P; Rosano, GM; Savarese, G; Trimarco, B | 1 |
| Azuma, J; Maegdefessel, L; Spin, JM; Tsao, PS | 1 |
| Ahrens, I; Lip, GY; Peter, K | 1 |
| Panchenko, EP | 1 |
| Connolly, SJ; Ezekowitz, MD; Reilly, PA; Wallentin, L; Yusuf, S | 1 |
| Pendleton, RC; Rodgers, GM; Smock, KJ; Wilcox, R | 1 |
| Connolly, SJ; Eikelboom, JW; Lamy, A; Margetts, P; Ricci, C; Warkentin, TE | 1 |
| Rami, BK | 1 |
| Livio, F | 1 |
14 review(s) available for dabigatran and Cardiovascular Diseases
| Article | Year |
|---|---|
The Efficacy and Safety of 3 Types of Interventions for Stroke Prevention in Patients With Cardiovascular and Cerebrovascular Diseases: A Network Meta-analysis.
Topics: Anticoagulants; Aspirin; Bayes Theorem; Cardiovascular Diseases; Clopidogrel; Dabigatran; Dipyridamole; Hemorrhage; Humans; Odds Ratio; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Thiazoles; Ticlopidine; Treatment Outcome; Warfarin | 2017 |
Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy.
Topics: Adenosine; Aspirin; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Clopidogrel; Dabigatran; Drug Interactions; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proton Pump Inhibitors; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Warfarin | 2013 |
Perioperative management of anticoagulation in elective surgery.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Blood Loss, Surgical; Cardiovascular Diseases; Clopidogrel; Dabigatran; Elective Surgical Procedures; Humans; Perioperative Care; Platelet Aggregation Inhibitors; Postoperative Complications; Risk Assessment; Thromboembolism; Ticlopidine; Withholding Treatment | 2013 |
Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Cost-Benefit Analysis; Dabigatran; Drug Costs; Hemorrhage; Humans; Markov Chains; Middle Aged; Morpholines; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiophenes; Time Factors; Warfarin | 2013 |
Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
Topics: Administration, Oral; Animals; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Stroke; Thiophenes | 2014 |
New oral anticoagulants and oculoplastic surgery.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Cataract Extraction; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridones; Rivaroxaban; Surgery, Plastic; Thiophenes | 2014 |
Dabigatran etexilate and risk of myocardial infarction, other cardiovascular events, major bleeding, and all-cause mortality: a systematic review and meta-analysis of randomized controlled trials.
Topics: Benzimidazoles; Cardiovascular Diseases; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Mortality; Myocardial Infarction; Pyridines; Randomized Controlled Trials as Topic; Risk Factors; Venous Thromboembolism | 2014 |
Incorporating edoxaban into the choice of anticoagulants for atrial fibrillation.
Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Dabigatran; Embolism; Factor Xa Inhibitors; Female; Humans; Intracranial Hemorrhages; Male; Pyrazoles; Pyridines; Pyridones; Research Design; Rivaroxaban; Stroke; Thiazoles; Warfarin | 2016 |
Reversal of Newer Direct Oral Anticoagulant Drugs (DOACs).
Topics: Administration, Oral; Animals; Antibodies, Monoclonal, Humanized; Anticoagulants; Antifibrinolytic Agents; Arginine; Blood Coagulation; Blood Coagulation Factors; Cardiovascular Diseases; Dabigatran; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Humans; Models, Molecular; Piperazines; Recombinant Proteins | 2017 |
Efficacy and Safety of Novel Oral Anticoagulants in Patients With Atrial Fibrillation and Heart Failure: A Meta-Analysis.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Cardiovascular Diseases; Cause of Death; Dabigatran; Embolism; Factor Xa Inhibitors; Heart Failure; Hemorrhage; Humans; Intracranial Hemorrhages; Mortality; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Treatment Outcome; Warfarin | 2016 |
New options with dabigatran etexilate in anticoagulant therapy.
Topics: Administration, Oral; Animals; Anticoagulants; Benzimidazoles; Blood Coagulation; Cardiovascular Diseases; Dabigatran; Drug Administration Schedule; Drug Interactions; Fibrinolytic Agents; Hemorrhage; Humans; Pyridines; Thrombin; Treatment Outcome | 2010 |
New oral anticoagulant drugs in cardiovascular disease.
Topics: Administration, Oral; Animals; Anticoagulants; Benzimidazoles; Cardiovascular Diseases; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Prothrombin; Pyridines; Rivaroxaban; Thiophenes; Vitamin K | 2010 |
Hospital-based clinical implications of the novel oral anticoagulant, dabigatran etexilate, in daily practice.
Topics: Antithrombins; Benzimidazoles; Blood Coagulation Tests; Cardiovascular Diseases; Clinical Trials as Topic; Dabigatran; Dose-Response Relationship, Drug; Enoxaparin; Humans; Pyridines; Venous Thromboembolism; Warfarin | 2011 |
[Pharmacovigilance update].
Topics: Adrenergic Uptake Inhibitors; Age Factors; Aged; Amides; Antihypertensive Agents; Atomoxetine Hydrochloride; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Dabigatran; Drug-Related Side Effects and Adverse Reactions; Fibrinolytic Agents; Fumarates; Hemorrhage; Humans; Pharmacovigilance; Propylamines | 2013 |
23 other study(ies) available for dabigatran and Cardiovascular Diseases
| Article | Year |
|---|---|
Atrial fibrillation, an equivalent of cardiovascular disease risk.
Topics: Anticoagulants; Atrial Fibrillation; Blood Pressure; Cardiovascular Diseases; Dabigatran; Humans; Thrombin; Warfarin | 2020 |
Switching across direct oral anticoagulants: a real-life-setting pilot prospective study.
Topics: Age Factors; Aged; Aged, 80 and over; Cardiovascular Diseases; Dabigatran; Drug Monitoring; Drug Substitution; Drug-Related Side Effects and Adverse Reactions; Factor Xa Inhibitors; Female; Heart Disease Risk Factors; Humans; Italy; Long Term Adverse Effects; Male; Medication Therapy Management; Risk Adjustment; Rivaroxaban | 2021 |
Prescribing of NOACs has outnumbered warfarin: exploring how physicians choose anticoagulant treatments.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Cardiovascular Diseases; Clinical Decision-Making; Dabigatran; Drug Monitoring; Drug Resistance; Factor Xa Inhibitors; Focus Groups; General Practitioners; Hemorrhage; Humans; Medical Staff, Hospital; Medication Adherence; Norway; Practice Patterns, Physicians'; Pyrazoles; Pyridones; Qualitative Research; Risk; Rivaroxaban; Warfarin | 2018 |
Role of Hypertension and Other Clinical Variables in Prognostication of Patients Presenting to the Emergency Department With Major Bleeding Events.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Blood Glucose; Blood Transfusion; Cardiovascular Diseases; Creatinine; Dabigatran; Emergency Service, Hospital; Epistaxis; Female; Gastrointestinal Hemorrhage; Hematuria; Hemoptysis; Hemorrhage; Humans; Hypertension; Intracranial Hemorrhages; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Prognosis; Propensity Score; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Severity of Illness Index; Sex Factors; Thiazoles; Warfarin | 2018 |
[NOAC in combination with platelet antiaggregation in both patients with coronary and peripheral arterial disease].
Topics: Acute Coronary Syndrome; Anticoagulants; Antithrombins; Cardiovascular Diseases; Coronary Artery Disease; Dabigatran; Drug Therapy, Combination; Factor Xa Inhibitors; Humans; Myocardial Infarction; Myocardial Ischemia; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Sweden; Thiazoles | 2018 |
Comparative clinical outcomes between direct oral anticoagulants and warfarin among elderly patients with non-valvular atrial fibrillation in the CMS medicare population.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Cardiovascular Diseases; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Medicare; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Treatment Outcome; United States; Warfarin | 2019 |
[Your patient needs antithrombotics, 2. What do the new substances offer? (interview by Dr. med. Peter Stiefelhagen)].
Topics: Adenosine; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Clopidogrel; Dabigatran; Fibrinolytic Agents; Guideline Adherence; Humans; Morpholines; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Rivaroxaban; Thiophenes; Thromboembolism; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
The use, misuse and abuse of dabigatran.
Topics: Advertising; Anticoagulants; Antithrombins; Aspirin; Australia; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Dabigatran; Drug Interactions; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Patient Selection; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Renal Insufficiency; Research Design; Selection Bias; Stroke; Warfarin | 2013 |
Comparative effectiveness of dabigatran, rivaroxaban, apixaban, and warfarin in the management of patients with nonvalvular atrial fibrillation.
Topics: Age Factors; Aged; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Comorbidity; Computer Simulation; Dabigatran; Female; Hemorrhage; Humans; Male; Morpholines; Pyrazoles; Pyridones; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Rivaroxaban; Thiophenes; Time Factors; Warfarin | 2013 |
[New oral anticoagulants in nonvalvular atrial fibrillation].
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Dabigatran; Humans; Pyrazoles; Pyridones; Stroke | 2013 |
Life-threatening epistaxis and red blood cell polyagglutination under dabigatran.
Topics: Aged, 80 and over; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Dabigatran; Epistaxis; Female; Humans | 2014 |
Dabigatran etexilate: An alternative to warfarin for patients with nonvalvular atrial fibrillation.
Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Cardiovascular Diseases; Dabigatran; Hemorrhage; Humans; Stroke; Warfarin | 2015 |
[Prospective study of the new oral anticoagulants in private practice: cautious optimism].
Topics: Administration, Oral; Anticoagulants; Antithrombins; Cardiology; Cardiovascular Diseases; Dabigatran; Factor Xa Inhibitors; Female; France; General Practice; Humans; Male; Middle Aged; Practice Patterns, Physicians'; Prospective Studies; Pyrazoles; Pyridones; Rivaroxaban; Surveys and Questionnaires; Thromboembolism; Treatment Outcome | 2015 |
Use of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients: insights from a specialist atrial fibrillation clinic.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cardiovascular Diseases; Clinical Audit; Dabigatran; Drug Substitution; Female; Fibrinolytic Agents; Hemorrhage; Humans; Ischemic Attack, Transient; Male; Middle Aged; Pyrazoles; Pyridones; Retrospective Studies; Risk Factors; Rivaroxaban; Stroke; Warfarin | 2015 |
The evolving role of dabigatran etexilate in clinical practice.
Topics: Antithrombins; Arthroplasty, Replacement, Knee; Atrial Fibrillation; Cardiovascular Diseases; Clinical Trials as Topic; Dabigatran; Enoxaparin; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Venous Thromboembolism | 2015 |
Cardiovascular, Bleeding, and Mortality Risks of Dabigatran in Asians With Nonvalvular Atrial Fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Asian People; Atrial Fibrillation; Brain Ischemia; Cardiovascular Diseases; Case-Control Studies; Dabigatran; Databases, Factual; Female; Gastrointestinal Hemorrhage; Hemorrhage; Hospitalization; Humans; Intracranial Hemorrhages; Logistic Models; Male; Middle Aged; Mortality; Myocardial Infarction; Proportional Hazards Models; Risk Factors; Stroke; Taiwan; Warfarin | 2016 |
The safety and persistence of non-vitamin-K-antagonist oral anticoagulants in atrial fibrillation patients treated in a well structured atrial fibrillation clinic.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Cardiovascular Diseases; Dabigatran; Female; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Patient Safety; Pyrazoles; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Treatment Outcome; Vitamin K | 2016 |
Thrombelastography detects dabigatran at therapeutic concentrations in vitro to the same extent as gold-standard tests.
Topics: Adult; Antithrombins; Blood Coagulation; Cardiovascular Diseases; Dabigatran; Drug Monitoring; Female; Humans; Male; Middle Aged; Reference Standards; Thrombelastography | 2016 |
[Anticoagulant therapy in cardiology: yesterday, today, tomorrow].
Topics: Anticoagulants; Benzimidazoles; Carboxypeptidase B2; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Dabigatran; Fibrinolytic Agents; Humans; Morpholines; Pyridines; Receptor, PAR-1; Rivaroxaban; Thiophenes; Thrombin; Thrombomodulin; Thrombosis; Treatment Outcome; Warfarin | 2010 |
Newly identified events in the RE-LY trial.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; Cardiovascular Diseases; Dabigatran; Embolism; Hemorrhage; Humans; Myocardial Infarction; Pyridines | 2010 |
I recently heard that there are alternative medications to the blood thinner warfarin. What are they, and how are they different?
Topics: Anticoagulants; Benzimidazoles; Cardiovascular Diseases; Dabigatran; Drug Approval; Drug Interactions; Food-Drug Interactions; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiophenes; Warfarin | 2012 |
Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding.
Topics: Aged; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Dabigatran; Factor VIIa; Humans; Male; Postoperative Hemorrhage; Recombinant Proteins; Renal Dialysis; Treatment Outcome | 2012 |
Direct thrombin inhibitors' potential efficacy in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Dabigatran; Endothelium, Vascular; Heparin; Humans; Thrombin | 2012 |